CHMP Favors Kesimpta for Adults With Relapsing MS in Europe

CHMP Favors Kesimpta for Adults With Relapsing MS in Europe

284841

CHMP Favors Kesimpta for Adults With Relapsing MS in Europe

A branch of the European Medicines Agency (EMA) has recommended that Kesimpta (ofatumumab) be approved and made available to treat relapsing forms of multiple sclerosis (MS) in adults with active disease. A final decision from the European Commission (EC) is expected in about two months. Typically, the EC follows opinions by the EMA’s Committee for Medicinal Products for Human Use (CHMP), which issued the recommendation. “The positive CHMP opinion for Kesimpta underscores its potential to provide…

You must be logged in to read/download the full post.